Uniaxially-aligned nanofiber scaffolds and methods for producing and using same

An implantable scaffold, comprising:

• a plurality of uniaxially aligned nanofibers, wherein all the nanofibers within the plurality of nanofibers are uniaxially aligned,
• wherein the plurality of nanofibers comprises polycaprolactone (PCL), poly (lactic-co-glycolic-acid) (PLGA), and between 1.7 and 2.2 μg of an S1P1 agonist,
• wherein the S1P1 agonist is differentially released for controlled release with an initial burst release in the first hours, followed by a delay, and a second phase of release occurring between 3 and 5 days following implantation,
• wherein the plurality of nanofibers is configured to release between 93.87% and 94.78% of the S1P1 agonist within the first 24 hours following implantation;
• and
• wherein the S1P1 agonist is FTY720.

An implantable scaffold, comprising:

• a plurality of uniaxially aligned nanofibers forming a flat portion having a diameter of between 1 mm and 23 mm, all of the nanofibers within the plurality of nanofibers being uniaxially aligned;
• wherein each of the plurality of nanofibers comprises polycaprolactone (PCL), poly (lactic-co-glycolic-acid) (PLGA), and an S1P1 agonist,
• wherein the S1P1 agonist is differentially released with an initial burst release in the first hours, followed by a delay, and a second phase of release occurring between 3 and 5 days;
• wherein the S1P1 agonist is FTY720;
• wherein the plurality of nanofibers is configured to release between 93.87% and 94.78% of the S1P1 agonist within the first 24 hours following implantation, and
• wherein the implantable scaffold selectively recruits LY6Clo monocytes and M2 macrophages to an implantation site.